One dose of gene-editing drug cut bad cholesterol 62% for months in small trial

Tech | Source: Arstechnica

One Dose of Gene-Editing Drug Cut Bad Cholesterol 62% for Months in Small Trial A new gene-editing therapy has shown promising results in reducing bad cholesterol levels by 62% with a single infusion, offering hope for a long-term solution to lowering cardiovascular disease risk.

The interim Phase I trial data, although limited to just 35 people, has yielded positive results, with the experimental gene-editing therapy, VERVE-102, appearing to be safe and effective in reducing bad cholesterol levels. The trial, which was published in the New England Journal of Medicine, reported no serious adverse events from the treatment, even at the largest doses. The most significant finding was a temporary, mild increase of a liver enzyme, suggesting minor injury in the liver, where the drug works. This side effect is not uncommon in gene-editing therapies and is often a sign that the drug is working as intended.

The small amount of data collected so far hints that the drug is effective in reducing bad cholesterol levels. The subgroup of participants who received the largest dose of VERVE-102 saw their low-density lipoprotein (LDL) levels drop by 62%, to a mean of 78 mg per deciliter. This reduction is significant, as it could cut the risk of cardiovascular disease from plaque buildup in arteries by an estimated 50% if sustained for over 20 years. The trial has only up to 18 months of follow-up data, but the positive effects of VERVE-102 seem to be holding up, with LDL reductions sustained in all subgroups.

The potential implications of this gene-editing therapy are substantial. High cholesterol is a major risk factor for cardiovascular disease, which is the leading cause of death worldwide. Current treatments for high cholesterol, such as statins, can be effective but often require lifelong administration and can have side effects. A gene-editing therapy that can provide a long-term solution to lowering bad cholesterol levels with a single infusion could revolutionize the treatment of high cholesterol and reduce the risk of cardiovascular disease.

The mechanism of VERVE-102 is based on gene editing, which involves making precise changes to the DNA sequence of a gene to modify its function. In this case, the gene-editing therapy targets the PCSK9 gene, which plays a critical role in regulating LDL levels. By editing the PCSK9 gene, VERVE-102 aims to reduce the production of LDL, thereby lowering bad cholesterol levels. The fact that the therapy appears to be safe and effective in reducing LDL levels is a significant breakthrough and offers hope for a new approach to treating high cholesterol.

While the results of the trial are promising, it is essential to note that the data is still preliminary, and more research is needed to confirm the safety and efficacy of VERVE-102. The trial will continue to follow the participants for a longer period to assess the durability of the treatment effect and to monitor for any potential side effects. Additionally, larger trials will be needed to confirm the results and to establish the therapy's safety and efficacy in a broader population.

In conclusion, the interim results of the Phase I trial of VERVE-102 are encouraging, and the gene-editing therapy has shown promise in reducing bad cholesterol levels with a single infusion. While more research is needed to confirm the safety and efficacy of the therapy, the potential implications of this breakthrough are significant, and it could offer a new approach to treating high cholesterol and reducing the risk of cardiovascular disease. As the trial continues and more data becomes available, it will be exciting to see if VERVE-102 can live up to its promise and provide a long-term solution to lowering bad cholesterol levels.